Evidence map›Paper›PMID 40112195›Full record

ArticleBioconjugate chemistry2025

Linker Design Principles for the Precision Targeting of Oncogenic G-Quadruplex DNA with G4-Ligand-Conjugated Oligonucleotides.

Alva Abrahamsson, Andreas Berner, Justyna Golebiewska-Pikula, Namrata Chaudhari, Emelie Keskitalo, Cecilia Lindgren, Marcin K Chmielewski, Sjoerd Wanrooij, Erik Chorell

Abstract read
In one paragraph

Article in Bioconjugate chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Light-Activated Molecules Targeting G-Quadruplex Nucleic Acids.Chemistry (Weinheim an der Bergstrasse, Germany) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alva AbrahamssonDepartment of Chemistry, Umeå University, SE-901 87 Umeå, Sweden.ORCID 0009-0004-3292-1637
Andreas BernerDepartments of Medical Biochemistry and Biophysics, Umea University, SE-907 36 Umeå, Sweden.ORCID 0000-0001-7864-8403
Justyna Golebiewska-PikulaDepartment of Chemistry, Umeå University, SE-901 87 Umeå, Sweden.
Namrata ChaudhariDepartments of Medical Biochemistry and Biophysics, Umea University, SE-907 36 Umeå, Sweden.
Emelie KeskitaloDepartment of Chemistry, Umeå University, SE-901 87 Umeå, Sweden.
Cecilia LindgrenDepartment of Chemistry, Umeå University, SE-901 87 Umeå, Sweden.
Marcin K ChmielewskiInstitute of Bioorganic Chemistry, Polish Academy of Sciences, Noskowskiego 12/14, 61-704 Poznan, Poland.ORCID 0000-0001-5717-7139
Sjoerd WanrooijDepartments of Medical Biochemistry and Biophysics, Umea University, SE-907 36 Umeå, Sweden.ORCID 0000-0001-6126-4382
Erik ChorellDepartment of Chemistry, Umeå University, SE-901 87 Umeå, Sweden.ORCID 0000-0003-2523-1940

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

G-quadruplex (G4) DNA structures are noncanonical secondary structures found in key regulatory regions of the genome, including oncogenic promoters and telomeres. Small molecules, known as G4 ligands, capable of stabilizing G4s hold promise as chemical probes and therapeutic agents. Nevertheless, achieving precise specificity for individual G4 structures within the human genome remains a significant challenge. To address this, we expand upon G4-ligand-conjugated oligonucleotides (GL-Os), a modular platform combining the stabilizing properties of G4-ligands with the sequence specificity of guide DNA oligonucleotides. Central to this strategy is the linker that bridges the G4 ligand and the guide oligonucleotide. In this study, we develop multiple conjugation strategies for the GL-Os that enabled a systematic investigation of the linker in both chemical composition and length, enabling a thorough assessment of their impact on targeting oncogenic G4 DNA. Biophysical, biochemical, and computational evaluations revealed GL-Os with optimized linkers that exhibited enhanced binding to target G4s, even under thermal or structural stress. Notably, longer linkers broadened the range of targetable sequences without introducing steric hindrance, thereby enhancing the platform's applicability across diverse genomic contexts. These findings establish GL-Os as a robust and versatile tool for the selective targeting of individual G4s. By facilitating precise investigations of G4 biology, this work provides a foundation for advancing G4-targeted therapeutic strategies and exploring their role in disease contexts.

Indexed as

DNADrug DesignG-QuadruplexesOligonucleotidesHumansLigandsDNALigandsOligonucleotides

Identifiers

PMID40112195
PMCPMC12006964

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.